PMID- 29785539
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2193-8261 (Print)
IS  - 2193-6544 (Electronic)
IS  - 2193-6544 (Linking)
VI  - 7
IP  - 1
DP  - 2018 Jun
TI  - The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in 
      Patients Undergoing Cardiac Catheterization: Study Design and Rationale.
PG  - 101-106
LID - 10.1007/s40119-018-0112-3 [doi]
AB  - INTRODUCTION: Patients undergoing coronary catheterization are at high risk of 
      developing contrast-induced nephropathy (CIN) acute kidney injury (AKI). Several 
      approaches have been supposed to limit such an effect but with mixed results or 
      non-practical methods. Spironolactone is supposed to be effective as a 
      nephroprotective agent in animal studies. This study will try to measure the 
      effect of spironolactone on the incidence of CIN-AKI in patients undergoing 
      coronary catheterization (angiography angioplasty). METHODS: This study is a 
      single-center, investigator-driven, double-blinded randomized controlled study in 
      Iraq-Basra. More than 400 patients admitted for coronary angio unit in our center 
      will be allocated in a 1:1 ratio to receive either spironolactone 200 mg single 
      dose or placebo in addition to their usual premedication. PLANNED OUTCOMES: 
      Primary end point will be CIN defined as more than 25% or 0.3 mg/dl elevation in 
      serum creatinine (S.Cr.) from baseline during the first 2-3 days after the 
      procedure. We hope to identify or answer an important question regarding CIN in 
      such high-risk patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier, 
      NCT03329443.
FAU - Mujtaba, Alhasan
AU  - Mujtaba A
AUID- ORCID: 0000-0003-0819-1780
AD  - Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, 
      Basra, Iraq. user11126@gmail.com.
FAU - Taher, Mohammed A
AU  - Taher MA
AD  - Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, 
      Basra, Iraq.
FAU - Hazza, Mazin A
AU  - Hazza MA
AD  - College of Medicine, University of Basra, Basra, Iraq.
FAU - Al-Rubaye, Hassan M
AU  - Al-Rubaye HM
AD  - Basra Cardiac Catheterization Center, Basra, Iraq.
FAU - Kata, Asaad H
AU  - Kata AH
AD  - Basra Cardiac Catheterization Center, Basra, Iraq.
FAU - AbdulWahab, Hamid
AU  - AbdulWahab H
AD  - Basra Cardiac Catheterization Center, Basra, Iraq.
FAU - AbdulBari, AbdulAmeer
AU  - AbdulBari A
AD  - College of Medicine, University of Basra, Basra, Iraq.
FAU - AlRubay, Hayder K
AU  - AlRubay HK
AD  - AlSader Teaching Hospital, Basra, Iraq.
LA  - eng
SI  - ClinicalTrials.gov/NCT03329443
PT  - Journal Article
DEP - 20180521
PL  - England
TA  - Cardiol Ther
JT  - Cardiology and therapy
JID - 101634495
PMC - PMC5986677
OTO - NOTNLM
OT  - Acute kidney injury (AKI)
OT  - Aldactone
OT  - Angiography
OT  - Angioplasty
OT  - Contrast-induced nephropathy (CIN)
OT  - Ischemic heart disease (IHD)
OT  - Percutaneous coronary angiography (PCI)
OT  - Spironolactone
EDAT- 2018/05/23 06:00
MHDA- 2018/05/23 06:01
PMCR- 2018/05/21
CRDT- 2018/05/23 06:00
PHST- 2018/04/11 00:00 [received]
PHST- 2018/05/23 06:00 [pubmed]
PHST- 2018/05/23 06:01 [medline]
PHST- 2018/05/23 06:00 [entrez]
PHST- 2018/05/21 00:00 [pmc-release]
AID - 10.1007/s40119-018-0112-3 [pii]
AID - 112 [pii]
AID - 10.1007/s40119-018-0112-3 [doi]
PST - ppublish
SO  - Cardiol Ther. 2018 Jun;7(1):101-106. doi: 10.1007/s40119-018-0112-3. Epub 2018 
      May 21.